Key Takeaways
- • Aidoc closed a $150 million Series E funding round led by Goldman Sachs' Growth Equity division, bringing total capital raised to over $500 million and positioning the Israeli clinical AI company for IPO consideration.
- • The round included participation from General Catalyst, SoftBank Vision Fund 2, and NVIDIA Ventures, signaling institutional confidence in Aidoc's clinical foundation model CARE and its enterprise platform aiOS.
- • Aidoc's CARE foundation model received FDA clearance earlier in 2026 for a comprehensive double-digit triage system in clinical imaging and currently analyzes over 60 million patient cases annually across nearly 2,000 hospitals.
- • The funding addresses a critical market need: diagnostic errors and delays contribute to an estimated 400,000 deaths annually in the U.S., driven by rising imaging volumes, workforce shortages, and increasing clinical complexity.
- • This Series E round closed less than a year after Aidoc's prior growth financing, reflecting accelerating enterprise demand for scaled clinical AI solutions that move beyond single-use-case applications.
Summary
Aidoc, an Israeli clinical artificial intelligence company, has secured $150 million in Series E financing led by Goldman Sachs' Growth Equity unit, according to announcements from the company and coverage by Globes English and supplemental sources. The round marks a significant milestone for the healthcare AI sector and brings Aidoc's cumulative fundraising to over $500 million. Beyond Goldman Sachs, the financing included participation from General Catalyst, SoftBank Vision Fund 2, and NVentures (NVIDIA's venture arm), demonstrating broad institutional backing from both financial and technology investors.
Aidoc's core offering centers on CARE, a proprietary clinical foundation model designed to reduce diagnostic errors and improve decision-making speed across health systems. The company has deployed this technology through aiOS, its enterprise platform, which operates across nearly 2,000 hospitals globally. According to company data, the platform currently analyzes more than 60 million patient cases annually. Earlier in 2026, CARE achieved FDA clearance for a comprehensive, double-digit foundation model-based triage system focused on clinical imaging—a significant regulatory validation that distinguishes Aidoc from competitors pursuing narrower, single-use-case applications.
The funding round addresses a substantial clinical and economic problem: diagnostic errors and delays are estimated to contribute to at least 400,000 preventable deaths annually in the United States, driven by surging imaging volumes, healthcare workforce shortages, and rising diagnostic complexity. Unlike earlier generations of medical AI tools that tackled isolated use cases, Aidoc's foundation model approach aims to deliver impact at enterprise scale. CEO Elad Walach stated the company's vision that "by 2030, every complex diagnostic decision should be supported by AI that enables earlier detection and reduces preventable error," underscoring both the clinical imperative and commercial ambition behind the raise.
The timing of this Series E—arriving less than a year after Aidoc's prior growth round led by General Catalyst and Square Peg—reflects accelerating market adoption and investor appetite for enterprise-grade clinical AI platforms. Market observers have noted that this funding round positions Aidoc for potential public market entry, suggesting that investors view the company's clinical foundation model, regulatory approvals, and hospital deployment base as assets capable of supporting a significant public valuation.
Aidoc's core offering centers on CARE, a proprietary clinical foundation model designed to reduce diagnostic errors and improve decision-making speed across health systems. The company has deployed this technology through aiOS, its enterprise platform, which operates across nearly 2,000 hospitals globally. According to company data, the platform currently analyzes more than 60 million patient cases annually. Earlier in 2026, CARE achieved FDA clearance for a comprehensive, double-digit foundation model-based triage system focused on clinical imaging—a significant regulatory validation that distinguishes Aidoc from competitors pursuing narrower, single-use-case applications.
The funding round addresses a substantial clinical and economic problem: diagnostic errors and delays are estimated to contribute to at least 400,000 preventable deaths annually in the United States, driven by surging imaging volumes, healthcare workforce shortages, and rising diagnostic complexity. Unlike earlier generations of medical AI tools that tackled isolated use cases, Aidoc's foundation model approach aims to deliver impact at enterprise scale. CEO Elad Walach stated the company's vision that "by 2030, every complex diagnostic decision should be supported by AI that enables earlier detection and reduces preventable error," underscoring both the clinical imperative and commercial ambition behind the raise.
The timing of this Series E—arriving less than a year after Aidoc's prior growth round led by General Catalyst and Square Peg—reflects accelerating market adoption and investor appetite for enterprise-grade clinical AI platforms. Market observers have noted that this funding round positions Aidoc for potential public market entry, suggesting that investors view the company's clinical foundation model, regulatory approvals, and hospital deployment base as assets capable of supporting a significant public valuation.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.